Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects

Mark R. Schleiss; David I. Bernstein; Murray Passo; Susan Parker; Claude Meric; François Verdier; Marianna M. Newkirk

doi:10.1016/j.vaccine.2004.06.038

Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects

Mark R. Schleiss, David I. Bernstein, Murray Passo, Susan Parker, Claude Meric, François Verdier, Marianna M. Newkirk

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Possible correlations have been proposed between autoimmune diseases, such as systemic lupus erythematosus (SLE), and infection with human cytomegalovirus (CMV). The recent observation that an adenovirus expressing the immunodominant envelope glycoprotein of CMV, glycoprotein B (gB), may be capable of inducing autoantibodies in certain mouse strains has prompted interest in exploring potential relationships between gB immunization and autoimmune disease. We examined whether a recombinant CMV gB vaccine, or a gB canarypox vectored vaccine (ALVAC-CMVgB), administered to a total of 76 CMV-seronegative subjects, was capable of inducing cross-reactive antibodies to Smith antigen (Sm), ribonucleoprotein complex (RNP), and the U1-70 kDa component of the RNP complex. Using immunofluorescence, EIA and immunoblot analyses, we failed to identify induction of autoantibodies following vaccination with gB, whether administered alone as a purified protein subunit with adjuvant, or in combination with expression in a vectored approach using a recombinant canarypox. These data reinforce the favorable safety profile of CMV gB vaccines.

Original language	English (US)
Pages (from-to)	687-692
Number of pages	6
Journal	Vaccine
Volume	23
Issue number	5
DOIs	https://doi.org/10.1016/j.vaccine.2004.06.038
State	Published - Dec 16 2004

Bibliographical note

Funding Information:
We acknowledge the assistance of Ginny McAlarney, Michele Woodard, and Milli Nath-Chowhury. We also thank Drs. Robert Hoffman and Eric Greidinger (University of Missouri, Columbia) for the analysis of the autoantibody responses, and Dominique Schulz for helpful discussions. Supported by a grant from Aventis Pasteur, and through the NIH VTEU network.

Keywords

Autoimmunity
CMV Vaccine
Cytomegalovirus
Glycoprotein B

Publisher link

10.1016/j.vaccine.2004.06.038

Find It

Find It at U of M Libraries

Cite this

@article{a66d46b64fce43abbb530fb25ed7fa77,

title = "Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects",

abstract = "Possible correlations have been proposed between autoimmune diseases, such as systemic lupus erythematosus (SLE), and infection with human cytomegalovirus (CMV). The recent observation that an adenovirus expressing the immunodominant envelope glycoprotein of CMV, glycoprotein B (gB), may be capable of inducing autoantibodies in certain mouse strains has prompted interest in exploring potential relationships between gB immunization and autoimmune disease. We examined whether a recombinant CMV gB vaccine, or a gB canarypox vectored vaccine (ALVAC-CMVgB), administered to a total of 76 CMV-seronegative subjects, was capable of inducing cross-reactive antibodies to Smith antigen (Sm), ribonucleoprotein complex (RNP), and the U1-70 kDa component of the RNP complex. Using immunofluorescence, EIA and immunoblot analyses, we failed to identify induction of autoantibodies following vaccination with gB, whether administered alone as a purified protein subunit with adjuvant, or in combination with expression in a vectored approach using a recombinant canarypox. These data reinforce the favorable safety profile of CMV gB vaccines.",

keywords = "Autoimmunity, CMV Vaccine, Cytomegalovirus, Glycoprotein B",

author = "Schleiss, {Mark R.} and Bernstein, {David I.} and Murray Passo and Susan Parker and Claude Meric and Fran{\c c}ois Verdier and Newkirk, {Marianna M.}",

note = "Funding Information: We acknowledge the assistance of Ginny McAlarney, Michele Woodard, and Milli Nath-Chowhury. We also thank Drs. Robert Hoffman and Eric Greidinger (University of Missouri, Columbia) for the analysis of the autoantibody responses, and Dominique Schulz for helpful discussions. Supported by a grant from Aventis Pasteur, and through the NIH VTEU network. ",

year = "2004",

month = dec,

day = "16",

doi = "10.1016/j.vaccine.2004.06.038",

language = "English (US)",

volume = "23",

pages = "687--692",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects

AU - Schleiss, Mark R.

AU - Bernstein, David I.

AU - Passo, Murray

AU - Parker, Susan

AU - Meric, Claude

AU - Verdier, François

AU - Newkirk, Marianna M.

N1 - Funding Information: We acknowledge the assistance of Ginny McAlarney, Michele Woodard, and Milli Nath-Chowhury. We also thank Drs. Robert Hoffman and Eric Greidinger (University of Missouri, Columbia) for the analysis of the autoantibody responses, and Dominique Schulz for helpful discussions. Supported by a grant from Aventis Pasteur, and through the NIH VTEU network.

PY - 2004/12/16

Y1 - 2004/12/16

N2 - Possible correlations have been proposed between autoimmune diseases, such as systemic lupus erythematosus (SLE), and infection with human cytomegalovirus (CMV). The recent observation that an adenovirus expressing the immunodominant envelope glycoprotein of CMV, glycoprotein B (gB), may be capable of inducing autoantibodies in certain mouse strains has prompted interest in exploring potential relationships between gB immunization and autoimmune disease. We examined whether a recombinant CMV gB vaccine, or a gB canarypox vectored vaccine (ALVAC-CMVgB), administered to a total of 76 CMV-seronegative subjects, was capable of inducing cross-reactive antibodies to Smith antigen (Sm), ribonucleoprotein complex (RNP), and the U1-70 kDa component of the RNP complex. Using immunofluorescence, EIA and immunoblot analyses, we failed to identify induction of autoantibodies following vaccination with gB, whether administered alone as a purified protein subunit with adjuvant, or in combination with expression in a vectored approach using a recombinant canarypox. These data reinforce the favorable safety profile of CMV gB vaccines.

AB - Possible correlations have been proposed between autoimmune diseases, such as systemic lupus erythematosus (SLE), and infection with human cytomegalovirus (CMV). The recent observation that an adenovirus expressing the immunodominant envelope glycoprotein of CMV, glycoprotein B (gB), may be capable of inducing autoantibodies in certain mouse strains has prompted interest in exploring potential relationships between gB immunization and autoimmune disease. We examined whether a recombinant CMV gB vaccine, or a gB canarypox vectored vaccine (ALVAC-CMVgB), administered to a total of 76 CMV-seronegative subjects, was capable of inducing cross-reactive antibodies to Smith antigen (Sm), ribonucleoprotein complex (RNP), and the U1-70 kDa component of the RNP complex. Using immunofluorescence, EIA and immunoblot analyses, we failed to identify induction of autoantibodies following vaccination with gB, whether administered alone as a purified protein subunit with adjuvant, or in combination with expression in a vectored approach using a recombinant canarypox. These data reinforce the favorable safety profile of CMV gB vaccines.

KW - Autoimmunity

KW - CMV Vaccine

KW - Cytomegalovirus

KW - Glycoprotein B

UR - http://www.scopus.com/inward/record.url?scp=8144226828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8144226828&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.06.038

DO - 10.1016/j.vaccine.2004.06.038

M3 - Article

C2 - 15542191

AN - SCOPUS:8144226828

SN - 0264-410X

VL - 23

SP - 687

EP - 692

JO - Vaccine

JF - Vaccine

IS - 5

ER -

Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this